Canada markets closed

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8016-0.0207 (-2.52%)
At close: 04:00PM EDT
0.8200 +0.02 (+2.30%)
After hours: 04:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8223
Bid0.7996 x 300
Ask0.8093 x 600
Day's Range0.7802 - 0.8472
52 Week Range0.6700 - 3.3300
Avg. Volume3,032,557
Market Cap87.029M
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-1.2400
Earnings DateAug 07, 2024 - Aug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.33
  • Simply Wall St.

    Gritstone bio First Quarter 2024 Earnings: Misses Expectations

    Gritstone bio ( NASDAQ:GRTS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.74m (down 29% from 1Q...

  • GlobeNewswire

    Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

    -- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 -- -- Nature Medicine publication of Phase 1 study of SLATE (off-the-shelf neoantigen vaccine) and AACR-presented improvements to EDGE™ (tumor antigen identification platform that was recently enhanced

  • GlobeNewswire

    Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

    -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To acce